Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AMYTNASDAQ:ARCTOTCMKTS:EMISNASDAQ:EWTXNASDAQ:RAPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsARCTArcturus Therapeutics$26.17-3.0%$34.18$17.52▼$43.81$704.50M2.6450,686 shs525,787 shsEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AEWTXEdgewise Therapeutics$15.94-1.1%$16.86$5.12▼$20.69$1.48B0.14916,373 shs605,170 shsRAPTRAPT Therapeutics$7.80-1.3%$9.58$6.86▼$27.35$271.44M0.471.15 million shs418,526 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics-3.40%-2.39%-22.45%-17.97%-3.92%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%EWTXEdgewise Therapeutics+2.94%+2.94%+0.69%+2.42%+107.07%RAPTRAPT Therapeutics-1.25%-1.74%-4.47%-67.00%-58.85%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/AARCTArcturus Therapeutics2.5507 of 5 stars3.52.00.00.02.23.30.6EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AEWTXEdgewise Therapeutics1.5915 of 5 stars3.51.00.00.02.62.50.0RAPTRAPT Therapeutics4.2558 of 5 stars4.32.00.03.62.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt PharmaN/AN/AN/AN/AARCTArcturus Therapeutics3.00Buy$61.33134.37% UpsideEMISEmisphere TechnologiesN/AN/AN/AN/AEWTXEdgewise Therapeutics3.00Buy$31.2095.73% UpsideRAPTRAPT Therapeutics2.50Moderate Buy$25.67229.06% UpsideCurrent Analyst RatingsLatest AMYT, EMIS, RAPT, ARCT, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.004/17/2024EWTXEdgewise TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.004/16/2024EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.004/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.003/20/2024ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/8/2024ARCTArcturus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/7/2024EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$48.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/21/2024RAPTRAPT TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$35.00 ➝ $13.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63ARCTArcturus Therapeutics$169.93M4.15N/AN/A$10.42 per share2.51EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/ARAPTRAPT Therapeutics$1.53M177.41N/AN/A$4.27 per share1.83Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/AARCTArcturus Therapeutics-$29.73M-$1.04N/A9.91N/A-15.65%-18.22%-11.95%5/14/2024 (Estimated)EMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AEWTXEdgewise Therapeutics-$100.16M-$1.58N/AN/AN/AN/A-32.06%-30.16%5/9/2024 (Estimated)RAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)Latest AMYT, EMIS, RAPT, ARCT, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/A2/22/2024Q4 2023EWTXEdgewise Therapeutics-$0.44-$0.47-$0.03-$0.47N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94ARCTArcturus TherapeuticsN/A4.724.72EMISEmisphere TechnologiesN/AN/AN/AEWTXEdgewise TherapeuticsN/A19.5019.50RAPTRAPT TherapeuticsN/A7.417.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%ARCTArcturus Therapeutics94.54%EMISEmisphere TechnologiesN/AEWTXEdgewise TherapeuticsN/ARAPTRAPT Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%ARCTArcturus Therapeutics13.80%EMISEmisphere Technologies72.90%EWTXEdgewise Therapeutics31.95%RAPTRAPT Therapeutics6.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableARCTArcturus Therapeutics18026.92 million23.20 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionableEWTXEdgewise Therapeutics8893.11 million63.36 millionOptionableRAPTRAPT Therapeutics13134.80 million32.50 millionOptionableAMYT, EMIS, RAPT, ARCT, and EWTX HeadlinesSourceHeadlineRAPT Therapeutics gets grant for inhibiting hematopoietic progenitor kinase 1 using pyrazole pyrimidine compoundspharmaceutical-technology.com - April 18 at 9:25 AMVertex buying Alpine for $4.9B for phase III-ready IgAN assetbioworld.com - April 12 at 8:27 AMHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertaintiesmarkets.businessinsider.com - April 12 at 8:27 AMRAPT reports positive phase 2 cancer trial resultsinvesting.com - April 11 at 1:51 AMMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertaintymarkets.businessinsider.com - April 10 at 8:50 PMRAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC Wainwrightmarketbeat.com - April 10 at 8:17 AMRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patientsglobenewswire.com - April 9 at 12:00 PMRapt Creative's glimpse of the past and nod to the futurebizcommunity.com - April 9 at 7:40 AM3 Biotech Stocks to Dump Before They Go to Zeroinvestorplace.com - April 9 at 6:31 AMRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - April 4 at 2:31 AMShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 32.5%marketbeat.com - April 1 at 8:31 AMRAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $13.00marketbeat.com - March 27 at 10:59 AMFringe paceman Gannon savours WA's Shield three-peatillawarramercury.com.au - March 26 at 9:02 AMRAPT Apr 2024 10.000 putfinance.yahoo.com - March 16 at 8:39 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 11 at 6:06 PMLeap To Fame on his way to defending Grand Circuit titleharnesslink.com - March 11 at 8:04 AMHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concernsmarkets.businessinsider.com - March 11 at 8:04 AMRAPT Oct 2024 5.000 callfinance.yahoo.com - March 8 at 12:09 AMRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023investorplace.com - March 7 at 5:03 PMShould You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?zacks.com - March 7 at 9:41 AMRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 7 at 8:00 AMRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - March 5 at 4:30 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTprnewswire.com - March 3 at 10:15 AMRAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbusinesswire.com - February 26 at 4:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmryt PharmaNASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Arcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Emisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Edgewise TherapeuticsNASDAQ:EWTXEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.